Revakinagene for MacTel: Is the Benefit Worth the Cost?

High-cost therapies have consistently been approved for conditions with significant unmet medical need, particularly when irreversible loss of function, such as blindness, is imminent. Decisions are based not only on clinical efficacy but also on prevention of long-term societal costs and preservation of patient autonomy. Therefore, it is our opinion that the benefit of revakinagene is worth the premium cost.

By
Michael Colucciello, MD
Martin Friedlander, MD, PhD
Kristin Raming, MD
September 1, 2026
15 min

Retinal Physician

Overview

Revakinagene taroretcel-lwey (Encelto) is the first FDA-approved treatment for Macular Telangiectasia type 2 (MacTel), demonstrating significant reductions in photoreceptor loss. Clinical trials indicate a 55% reduction in the rate of photoreceptor loss at 24 months.

Background

Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative condition affecting central photoreceptors, leading to gradual visual decline. The disease is characterized by a slow progression of retinal damage.

Data Highlights

Study	Reduction in EZ Area Loss	P-Value
NTMT-03A	55%	P<.001
NTMT-03B	31%	P<.02

Key Findings

Revakinagene demonstrated a 55% reduction in photoreceptor loss at 24 months in phase 3 trials.
Serious adverse events occurred in 5% of patients, primarily related to the surgical procedure.
Dark adaptation was delayed in 17% to 24% of treated patients compared to 0% to 2% of controls.
Miosis was observed in 14% to 17% of treated patients, with none in the control group.

Clinical Implications

The approval of revakinagene provides a new therapeutic option for patients with MacTel, potentially slowing disease progression. Clinicians should monitor for surgical complications and assess visual function outcomes in treated patients.